Paolo Pertile : Citation Profile


Are you Paolo Pertile?

Università degli Studi di Verona

6

H index

3

i10 index

106

Citations

RESEARCH PRODUCTION:

19

Articles

19

Papers

RESEARCH ACTIVITY:

   17 years (2006 - 2023). See details.
   Cites by year: 6
   Journals where Paolo Pertile has often published
   Relations with other researchers
   Recent citing documents: 11.    Total self citations: 21 (16.54 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/ppe336
   Updated: 2024-11-04    RAS profile: 2023-10-22    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Gamba, Simona (4)

LEVAGGI, ROSELLA (4)

moretto, michele (2)

Magazzini, Laura (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Paolo Pertile.

Is cited by:

Straume, Odd Rune (12)

LEVAGGI, ROSELLA (10)

Cellini, Roberto (10)

Grilli, Luca (8)

Siciliani, Luigi (8)

Brekke, Kurt (6)

Forster, Martin (4)

Costa-Font, Joan (3)

Gamba, Simona (3)

Florio, Massimo (3)

Suárez-Varela, Marta (2)

Cites to:

LEVAGGI, ROSELLA (19)

moretto, michele (17)

Siciliani, Luigi (13)

Ziebarth, Nicolas (10)

Kotlikoff, Laurence (9)

Pichler, Stefan (9)

Bourguignon, François (9)

Johansson, Per (8)

Ma, Ching-to (8)

Claxton, Karl (7)

Dranove, David (7)

Main data


Where Paolo Pertile has published?


Journals with more than one article published# docs
Journal of Health Economics3
Health Economics3
Journal of Public Economic Theory2
Applied Health Economics and Health Policy2

Working Papers Series with more than one paper published# docs
Working Papers / University of Verona, Department of Economics11
Working Papers / Fondazione Eni Enrico Mattei2

Recent works citing Paolo Pertile (2024 and 2023)


YearTitle of citing document
2023The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets. (2023). Straume, Odd Rune ; Dalen, Dag Morten ; Brekke, Kurt R. In: Journal of Health Economics. RePEc:eee:jhecon:v:90:y:2023:i:c:s0167629623000553.

Full description at Econpapers || Download paper

2023Should Italy switch to a flat tax? An assessment based on a heterogeneous agents OLG model. (2023). Sommacal, Alessandro. In: European Journal of Political Economy. RePEc:eee:poleco:v:80:y:2023:i:c:s017626802300126x.

Full description at Econpapers || Download paper

2024Competition, value-based prices and incentives to research personalised drugs. (2024). Levaggi, Rosella. In: Socio-Economic Planning Sciences. RePEc:eee:soceps:v:93:y:2024:i:c:s0038012124000697.

Full description at Econpapers || Download paper

2023The role of patient organisations in research and development: Evidence from rare diseases. (2023). Miraldo, Marisa ; Gentilini, Arianna. In: Social Science & Medicine. RePEc:eee:socmed:v:338:y:2023:i:c:s0277953623006895.

Full description at Econpapers || Download paper

2024The role of the quality infrastructure within socio-technical transformations: A European perspective. (2024). Blind, Knut. In: Technological Forecasting and Social Change. RePEc:eee:tefoso:v:199:y:2024:i:c:s0040162523007047.

Full description at Econpapers || Download paper

2023The price of cost-effectiveness thresholds. (2023). Straume, Odd Rune ; Dalen, Dag Morten ; Brekke, Kurt R. In: Discussion Paper Series in Economics. RePEc:hhs:nhheco:2023_004.

Full description at Econpapers || Download paper

2024Favorable tax treatment of older workers in general equilibrium. (2024). Gustafsson, Johan. In: Umeå Economic Studies. RePEc:hhs:umnees:1023.

Full description at Econpapers || Download paper

2023Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts. (2023). Forster, Martin ; Chick, Stephen E ; Alban, Andres. In: Management Science. RePEc:inm:ormnsc:v:69:y:2023:i:6:p:3516-3535.

Full description at Econpapers || Download paper

2023Evaluation of a pharmaceutical risk‐sharing agreement when patients are screened for the probability of success. (2018). Zaric, Gregory S ; Degaard, Fredrik ; Mahjoub, Reza . In: Health Economics. RePEc:wly:hlthec:v:27:y:2018:i:1:p:e15-e25.

Full description at Econpapers || Download paper

2024An analysis of a rural hospitals investment decision under different payment systems. (2024). Guo, Xidong. In: Health Economics. RePEc:wly:hlthec:v:33:y:2024:i:4:p:714-747.

Full description at Econpapers || Download paper

Works by Paolo Pertile:


YearTitleTypeCited
2023Dynamic, incentive-compatible contracting for health services In: FEEM Working Papers.
[Full Text][Citation analysis]
paper0
2023Dynamic, incentive-compatible contracting for health services.(2023) In: Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 0
paper
2014Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies In: Journal of the Royal Statistical Society Series A.
[Full Text][Citation analysis]
article8
2017A Bayesian decision theoretic model of sequential experimentation with delayed response In: Journal of the Royal Statistical Society Series B.
[Full Text][Citation analysis]
article10
2015A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response.(2015) In: Discussion Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 10
paper
2008Investment in Health Technologies in a Competitive Model with Real Options In: Journal of Public Economic Theory.
[Full Text][Citation analysis]
article3
2017The Dynamics of Pharmaceutical Regulation and R&D Investments In: Journal of Public Economic Theory.
[Full Text][Citation analysis]
article5
2013The dynamics of pharmaceutical regulation and R&D investments.(2013) In: Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 5
paper
2014Two-part payments for the reimbursement of investments in health technologies In: Health Policy.
[Full Text][Citation analysis]
article8
2012Static and dynamic efficiency of irreversible health care investments under alternative payment rules In: Journal of Health Economics.
[Full Text][Citation analysis]
article13
2010Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules.(2010) In: Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 13
paper
2016Late-stage pharmaceutical R&D and pricing policies under two-stage regulation In: Journal of Health Economics.
[Full Text][Citation analysis]
article7
2015Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation.(2015) In: Discussion Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 7
paper
2021R&D and market size: Who benefits from orphan drug legislation? In: Journal of Health Economics.
[Full Text][Citation analysis]
article3
2017A large scale OLG model for the analysis of the redistributive effects of policy reforms In: European Journal of Political Economy.
[Full Text][Citation analysis]
article18
2006Technology adoption, quality and health care costs: a review of the literature In: STUDI ECONOMICI.
[Full Text][Citation analysis]
article1
2009The timing of adoption of positron emission tomography: a real options approach In: Health Care Management Science.
[Full Text][Citation analysis]
article1
2009An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography In: International Journal of Health Economics and Management.
[Full Text][Citation analysis]
article2
2015The fiscal disadvantage of young Italians: a new view on consolidation and fairness In: The Journal of Economic Inequality.
[Full Text][Citation analysis]
article1
2020Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article6
2020Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article0
2016Redistribution at the local level: the case of public childcare in Italy In: International Review of Economics.
[Full Text][Citation analysis]
article4
2013Redistribution at the Local Level: The Case of Public Childcare in Italy.(2013) In: Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 4
paper
2011Dynamic, economic approaches to HTA under uncertainty In: Working Papers.
[Full Text][Citation analysis]
paper0
2012Public finance consolidation and fairness across living generations: the case of Italy In: Working Papers.
[Full Text][Citation analysis]
paper0
2014L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC In: Working Papers.
[Full Text][Citation analysis]
paper3
2019R&D and market size: who benefits from orphan drug regulation? In: Working Papers.
[Full Text][Citation analysis]
paper1
2016Pricing policies when patients are heterogeneous: a welfare analysis In: Working Papers.
[Full Text][Citation analysis]
paper1
2015Who should monitor job sick leave? In: Working Papers.
[Full Text][Citation analysis]
paper0
2012Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution In: Working Papers.
[Full Text][Citation analysis]
paper0
2015Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden In: Working Papers.
[Full Text][Citation analysis]
paper1
2012DRGs: the link between investment in technologies and appropriateness In: Working Papers.
[Full Text][Citation analysis]
paper1
2013Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective In: Health Economics.
[Full Text][Citation analysis]
article4
2019Job sick leave: Detecting opportunistic behavior In: Health Economics.
[Full Text][Citation analysis]
article0
2020The impact of managed entry agreements on pharmaceutical prices In: Health Economics.
[Full Text][Citation analysis]
article2
2022Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany In: Health, Econometrics and Data Group (HEDG) Working Papers.
[Full Text][Citation analysis]
paper0
2010Optimal sequential sampling rules for the economic evaluation of health technologies In: Discussion Papers.
[Full Text][Citation analysis]
paper2
2018Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence In: Discussion Papers.
[Full Text][Citation analysis]
paper1

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team